Drug sales post healthy gains for 2006, but primary care categories slip

Share this article:
Global pharmaceutical sales grew 7% to $643 billion in 2006, according to IMS Health, while US drug sales were up 8.3% to $290.1 billion for the year, thanks to Medicare Part D and strong sales of specialty products -- particularly oncologics and autoimmune agents. Specialist-driven products contributed 62% of growth, compared with just 35% in 2000, the company said. Sales of oncologics were up 20.5% to $34.6 billion, with more than 380 compounds in development, including many targeted therapies in Phase III clinical trials. Autoimmune agents like Remicade and Humira were up 20% to $10.6 billion in sales, with a boost from new indications approved for existing medications. Respiratory drug sales were up 10% to $24.6 billion, and sales of lipid drugs continued to grow, up 7.5% to $35.2 billion. But some long-reliable primary-care cash cows slipped due to generic incursions and OTC switches, with PPIs, antihistamines, platelet aggregation inhibitors and antidepressants losing ground. And products worth $14 billion in US sales lost patent protection over the course of the year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...